Medical and sociodemographic factors predict persistent smoking after coronary events

[1] Doll R(2004)Mortality in relation to smoking: 50 years' observations on male British doctors BMJ 328 1519-np96

[2] Peto R(2016)2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur J Prev Cardiol 23 Np1-219

[3] Boreham J(2004)The problem of tobacco smoking BMJ 328 217-1425

[4] Sutherland I(2004)Smoking cessation for the secondary prevention of coronary heart disease Cochrane Database Syst Rev 1 CD003041-648

[5] Piepoli MF(2014)Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews Addiction 109 1414-940

[6] Hoes AW(2013)Pharmacological interventions for smoking cessation: an overview and network meta-analysis Cochrane Database Syst Rev 5 CD009329-234

[7] Agewall S(2012)Interventions for smoking cessation in hospitalised patients Cochrane Database Syst Rev 5 CD001837-3267

[8] Albus C(2016)EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries Eur J Prev Cardiol 23 636-1306

[9] Brotons C(2009)Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 929-2303

[10] Catapano AL(2010)Coronary mortality declines in the U.S. between 1980 and 2000 quantifying the contributions from primary and secondary prevention Am J Prev Med 39 228-415

[1] Doll R(2004)Mortality in relation to smoking: 50 years' observations on male British doctors BMJ 328 1519-np96

[2] Peto R(2016)2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur J Prev Cardiol 23 Np1-219

[3] Boreham J(2004)The problem of tobacco smoking BMJ 328 217-1425

[4] Sutherland I(2004)Smoking cessation for the secondary prevention of coronary heart disease Cochrane Database Syst Rev 1 CD003041-648

[5] Piepoli MF(2014)Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews Addiction 109 1414-940

[6] Hoes AW(2013)Pharmacological interventions for smoking cessation: an overview and network meta-analysis Cochrane Database Syst Rev 5 CD009329-234

[7] Agewall S(2012)Interventions for smoking cessation in hospitalised patients Cochrane Database Syst Rev 5 CD001837-3267

[8] Albus C(2016)EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries Eur J Prev Cardiol 23 636-1306

[9] Brotons C(2009)Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 929-2303

[10] Catapano AL(2010)Coronary mortality declines in the U.S. between 1980 and 2000 quantifying the contributions from primary and secondary prevention Am J Prev Med 39 228-415